Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Chromatin accessibility as potential markers of drug response in breast cancer
EF 2023-24
Résumé
Breast cancer is the most diagnosed cancer worldwide, and its complex nature demands personalized treatment strategies. While genetic profiles have assisted in tailoring cancer treatment, there are still subtypes without effective therapy options. Here, we propose chromatin accessibility as a new approach to stratifying patients based on underlying traits that govern cancer behaviour. We believe that chromatin features will serve as valuable biomarkers to predict patient response or resistance to different cancer drugs. To identify these chromatin accessibility features, I will first conduct pharmacogenomic analysis to obtain candidate signatures that predict drug response or resistance in breast cancer cell lines. These preclinical markers will be validated in mouse models and patient blood samples to assess their clinical viability. Finally, I will evaluate the accuracy of integrated chromatin accessibility and gene expression data in predicting drug response in independent cell lines. Leveraging chromatin-derived insights may facilitate the discovery of new genomic biomarkers to improve breast cancer treatment strategies and increase the pool of available therapeutic options. This workflow will also evaluate the translation of laboratory pharmacogenomic models into clinical use, aiding further biomarker discovery and advancing the field of precision oncology.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506380
Name
Nguyen Julia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Chromatin accessibility as potential markers of drug response in breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biomarker Discovery; Chemoresistance; Chromatin Accessibility; Epigenomics; Pharmacogenomics; Precision Oncology
Abstract
Breast cancer is the most diagnosed cancer worldwide, and its complex nature demands personalized treatment strategies. While genetic profiles have assisted in tailoring cancer treatment, there are still subtypes without effective therapy options. Here, we propose chromatin accessibility as a new approach to stratifying patients based on underlying traits that govern cancer behaviour. We believe that chromatin features will serve as valuable biomarkers to predict patient response or resistance to different cancer drugs. To identify these chromatin accessibility features, I will first conduct pharmacogenomic analysis to obtain candidate signatures that predict drug response or resistance in breast cancer cell lines. These preclinical markers will be validated in mouse models and patient blood samples to assess their clinical viability. Finally, I will evaluate the accuracy of integrated chromatin accessibility and gene expression data in predicting drug response in independent cell lines. Leveraging chromatin-derived insights may facilitate the discovery of new genomic biomarkers to improve breast cancer treatment strategies and increase the pool of available therapeutic options. This workflow will also evaluate the translation of laboratory pharmacogenomic models into clinical use, aiding further biomarker discovery and advancing the field of precision oncology.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nguyen, Julia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~